Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer

Molecular Cancer Therapeutics

Volumn 2, Issue 10, 2003, Pages 1011-1021

  Abrams, Tinya J ^a   Murray, Lesley J ^a   Pesenti, Enrico ^b   Holway, Vicky Walker ^b   Colombo, Tina ^c   Lee, Leslie B ^a   Cherrington, Julie M ^a   Pryer, Nancy K ^a  

^a SUGEN INC   (United States)

^b PFIZER INC   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; ENZYME INHIBITOR; FLUOROURACIL; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

ANIMAL; ARTICLE; BONE TUMOR; BREAST TUMOR; CANCER TRANSPLANTATION; FEMALE; HUMAN; METASTASIS; MOUSE; NUDE MOUSE; PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; TIME; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; INDOLES; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 2442669093     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mendel, D. B., Laird, A. D., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R. E., Abrams, T. J., Ngai, T. J., Lee, L. B., Murray, L. J., Carver, J., Chan, E., Moss, K. G., Haznedar, J. O., Sukbuntherng, J., Blake, R. A., Sun, C., Tang, C., Miller, T., Shirazian, S., McMahon, G., and Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res., 9: 327-337, 2003. (Pubitemid 36109749)
2. O'Farrell, A. M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W. M., Lee, L. B., Town, A., Smolich, B. D., Manning, W. C., Murray, L. J., Heinrich, M. C., and Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo . Blood, 101: 3597-3605, 2003. (Pubitemid 36857948)
3. Abrams, T., Lee, L. B., Murray, L. J., Pryer, N. K., and Cherrington, J. M. SU11248 inhibits KIT and platelet derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther., 2: 471-478, 2003.
4. Cherrington, J. M., Strawn, L. M., and Shawver, L. K. New paradigms for the treatment of cancer; the role of anti-angiogenesis agents. In: G. F. Vande Woude (ed.), Advances in Cancer Res., 1st edition, vol. 79, pp. 1-38. San Diego, CA: Academic Press, 2000.
5. Nakopoulou, L., Stefanaki, K., Panayotopoulou, E., Giannopoulou, I., Athanassiadou, P., Gakiopoulou-Givalou, H., and Louvrou, A. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation (Comment). Hum. Pathol., 33: 863-870, 2002.
6. de Jong, J. S., van Diest, P. J., van der Valk, P., and Baak, J. P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I. An inventory in search of autocrine and paracrine loops. J. Pathol., 184: 44-52, 1998. (Pubitemid 28086152)
7. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Connolly, J. L., and Schnitt, S. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 26: 86-91, 1995.
8. Kranz, A., Mattfeldt, T., and Waltenberger, J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int. J. Cancer, 84: 293-298, 1999. (Pubitemid 29256757)
9. Manders, P., Beex, L. V., Tjan-Heijnen, V. C., Geurts-Moespot, J., Van Tienoven, T. H., Foekens, J. A., and Sweep, C. G. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br. J. Cancer, 87: 772-778, 2002. (Pubitemid 35178755)
10. Coltrera, M. D., Wang, J., Porter, P. L., and Gown, A. M. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor β subunit in human breast tissue and breast carcinoma. Cancer Res., 55: 2703-2708, 1995.
11. Hines, S. J., Organ, C., Kornstein, M. J., and Krystal, G. W. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth & Differ., 6: 769-779, 1995.
12. Palmu, S., Soderstrom, K. O., Quazi, K., Isola, J., and Salminen, E. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res., 22: 411-414, 2002. (Pubitemid 34475331)
13. Natali, P. G., Nicotra, M. R., Sures, I., Mottolese, M., Botti, C., and Ullrich, A. Breast cancer is associated with loss of the c-kit oncogene product. Int. J. Cancer, 52: 713-717, 1992.
14. Chui, X., Egami, H., Yamashita, J., Kurizaki, T., Ohmachi, H., Yamamoto, S., and Ogawa, M. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br. J. Cancer, 73: 1233-1236, 1996. (Pubitemid 26162338)
15. Tsuura, Y., Suzuki, T., Honma, K., and Sano, M. Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status. J. Cancer Res. Clin. Oncol., 128: 239-246, 2002. (Pubitemid 34591581)
16. Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., and Leder, P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo . Cell, 49: 465-475, 1987. (Pubitemid 18091823)
17. Welsch, C. W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res., 45: 3415-3443, 1985. (Pubitemid 15226403)
18. Schmidt, C. M., Settle, S. L., Keene, J. L., Westlin, W. F., Nickols, G. A., and Griggs, D. W. Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry. Clin. & Exp. Metastasis, 17: 537-544, 1999. (Pubitemid 30182749)
19. Sasaki, A., Boyce, B. F., Story, B., Wright, K. R., Chapman, M., Boyce, R., Mundy, G. R., and Yoneda, T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res., 55: 3551-3557, 1995.
20. Crown, J., Dieras, V., Kaufmann, M., von Minckwitz, G., Kaye, S., Leonard, R., Marty, M., Misset, J. L., Osterwalder, B., and Piccart, M. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol., 3: 719-727, 2002. (Pubitemid 35446740)
21. Fidler, I. J. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res., 50: 6130-6138, 1990. (Pubitemid 20323663)
22. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999. (Pubitemid 29038270)
23. Sundberg, C., Ljungstrom, M., Lindmark, G., Gerdin, B., and Rubin, K. Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol., 143: 1377-1388, 1993. (Pubitemid 24057108)
24. Mendelsohn, J. and Fan, Z. Epidermal growth factor receptor family and chemosensitization (Comment) J. Natl. Cancer Inst., 89: 341-343, 1997. (Pubitemid 27102599)
25. Price, J. E. Metastasis from human breast cancer cell lines. Breast Cancer Res. Treat., 39: 93-102, 1996. (Pubitemid 26136507)
26. Hortobagyi, G. N. Bone metastases in breast cancer patients. Semin. Oncol., 18: 11-15, 1991.
27. Poitout, D. G. (ed.). Bone metastases: diagnosis and treatment, pp. 5-15. New York: Springer-Verlag, 1991.
28. Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., Blacklock, H. A., Bell, R., Simeone, J., Reitsma, D. J., Heffernan, M., Seaman, J., and Knight, R. D. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group (Comment). N. Engl. J. Med., 334: 488-493, 1996. (Pubitemid 26067736)
29. Mundy, G. R. and Bertolini, D. R. Bone destruction and hypercalcemia in plasma cell myeloma (Erratum appears in Semin. Oncol. 13 (4): lxiii, 1986). Semin. Oncol., 13: 291-299, 1986. (Pubitemid 17204707)